October 1, 2014 / 12:37 PM / 3 years ago

Portola Pharma drug reverses effect of anti-clotting drugs in study

Oct 1 (Reuters) - Portola Pharmaceuticals Inc said its drug met the main goal of reversing the effect of anti-coagulant drugs in a late-stage study.

Data showed that an intravenous shot of the drug, andexanet alfa, immediately reversed the effect of Eliquis, an anti-clotting drug by Bristol-Myers Squibb Co and Pfizer Inc.

Andexanet alfa is also being tested against Xarelto, a drug made by Bayer Healthcare and Johnson & Johnson’s unit Janssen, Portola said in a statement. (Reporting by Vidya L Nathan in Bangalore; Editing by Kirti Pandey)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below